In this e-learning, authors prof. Brian Rini and prof. Toni Choueiri. are queried by a panel of fellow oncologists about the recent results of the Keynote-426 and Javelin 101 Renal studies. In both phase III trials, the combination of an immunotherapy agent with the tyrosine kinase inhibitor axitinib was compared to sunitinib as first line treatment of advanced renal cell carcinoma. The panel of experts, led by prof. John Haanen, will thoroughly discuss the results of these trials with both authors. This program provides the opportunity to gain detailed knowledge of the Keynote-426 en Javelin 101 Renal trials. Together with the authors, the expert panel will offer profound insight into the setup and execution of both trials. They will discuss the different results and assess their impact on daily clinical practice. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Motzer RJ, Penkov K, Haanen J et al. N Engl J Med 2019; 380:1103-1115. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. Rini BI, Plimack ER, Stus V, et al. N Engl J Med 2019; 380:1116-1127. Authors Prof. Brian Rini, MD - medical oncologist, Vanderbilt-Ingram Cancer Center, Nashville, US; prof. Toni Choueiri, MD - medical oncologist, Dana-Farber Cancer Institute, Boston, US. Discussion panel Prof. John Haanen, MD, PhD - medical oncologist NKI-AvL, Amsterdam; Axel Bex, MD, PhD - urologic surgeon, Royal Free Hospital, London, UK; Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen.